Study evaluates effectiveness and safety of TMF for chronic hepatitis B

Chronic hepatitis B (CHB) remains a significant global health challenge, and effective antiviral therapies are essential for long-term management.

MASCT by Hengrui Yuanzheng Biotechnology for Ureter Cancer: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

January 8, 2024

Tuberculosis linked to increased risk of cancer, study finds

A population-wide observational study to be presented at this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) in Barcelona, Spain (27-30 April)

April 1, 2024

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs | Psychedelic Invest

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has entered into a conditional share sale

September 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.